Publications

BibTex format

@article{Coombes:2021:10.1001/jamaoncol.2021.2193,
author = {Coombes, RC and Tovey, H and Kilburn, L and Mansi, J and Palmieri, C and Bartlett, J and Hicks, J and Makris, A and Evans, A and Loibl, S and Denkert, C and Murray, E and Grieve, R and Coleman, R and Borley, A and Schmidt, M and Rautenberg, B and Kunze, CA and Rhein, U and Mehta, K and Mousa, K and Dibble, T and Lu, XL and von, Minckwitz G and Bliss, JM},
doi = {10.1001/jamaoncol.2021.2193},
journal = {JAMA Oncology},
pages = {1291--1301},
title = {Effect of celecoxib vs placebo as adjuvant therapy on disease-free survival among patients with breast cancer The REACT randomized clinical trial},
url = {http://dx.doi.org/10.1001/jamaoncol.2021.2193},
volume = {7},
year = {2021}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Importance  Patients with breast cancer remain at risk of relapse after adjuvant therapy. Celecoxib has shown antitumor effects in preclinical models of human breast cancer, but clinical evidence is lacking.Objective  To evaluate the role of celecoxib as an addition to conventional therapy for women with ERBB2 (formerly HER2)–negative primary breast cancer.Design, Setting, and Participants  The Randomized European Celecoxib Trial (REACT) was a phase 3, randomized, double-blind study conducted in 160 centers across the UK and Germany testing 2 years of adjuvant celecoxib vs placebo among 2639 patients recruited between January 19, 2007, and November 1, 2012, with follow-up 10 years after treatment completion. Eligible patients had completely resected breast cancer with local and systemic therapy according to local practice. Patients with ERBB2-positive or node-negative and T1, grade 1 tumors were not eligible. Randomization was in a 2:1 ratio between celecoxib or placebo. Statistical analysis was performed from May 5, 2019, to March 5, 2020.Interventions  Patients received celecoxib, 400 mg, or placebo once daily for 2 years.Main Outcomes and Measures  The primary end point was disease-free survival (DFS), analyzed in the intention-to-treat population using Cox proportional hazards regression and log-rank analysis. Follow-up is complete.Results  A total of 2639 patients (median age, 55.2 years [range, 26.8-86.0 years]) were recruited; 1763 received celecoxib, and 876 received placebo. Most patients’ tumors (1930 [73%]) were estrogen receptor positive or progesterone receptor positive and ERBB2 negative. A total of 1265 patients (48%) had node-positive disease, and 1111 (42%) had grade 3 tumors. At a median follow-up of 74.3 months (interquartile range, 61.4-93.6 years), DFS events had been reported for 487 patients (19%): 18% for those who received celecoxib (n = 323; 5-year DFS rate = 84%) vs 19% for those who received placebo
AU  - Coombes,RC
AU  - Tovey,H
AU  - Kilburn,L
AU  - Mansi,J
AU  - Palmieri,C
AU  - Bartlett,J
AU  - Hicks,J
AU  - Makris,A
AU  - Evans,A
AU  - Loibl,S
AU  - Denkert,C
AU  - Murray,E
AU  - Grieve,R
AU  - Coleman,R
AU  - Borley,A
AU  - Schmidt,M
AU  - Rautenberg,B
AU  - Kunze,CA
AU  - Rhein,U
AU  - Mehta,K
AU  - Mousa,K
AU  - Dibble,T
AU  - Lu,XL
AU  - von,Minckwitz G
AU  - Bliss,JM
DO  - 10.1001/jamaoncol.2021.2193
EP  - 1301
PY  - 2021///
SN  - 2374-2445
SP  - 1291
TI  - Effect of celecoxib vs placebo as adjuvant therapy on disease-free survival among patients with breast cancer The REACT randomized clinical trial
T2  - JAMA Oncology
UR  - http://dx.doi.org/10.1001/jamaoncol.2021.2193
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000673049400006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
UR  - https://jamanetwork.com/journals/jamaoncology/fullarticle/2781890
VL  - 7
ER  -

Download

ProfessorCharlesCoombes

Contact

Assistant

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)